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Background: The incidence of differentiated thyroid cancer (DTC) has rapidly increased 30 
worldwide over the last decades. It is unknown if the increase in diagnosis has been mirrored 31 
by an increase in thyroidectomy rates with the concomitant economic impact that this would 32 
have on the healthcare system. 33 
 34 
Methods: DTC and thyroidectomy incidence as well as DTC specific mortality were 35 
modelled using Poisson regression in New South Wales (NSW), Australia per year and by 36 
sex. The incidence of 2002 was the point from which the increase in rates were assessed 37 
cumulatively over the subsequent decade. The economic burden of potentially avoidable 38 
thyroidectomies due to the increase in diagnosis was estimated as the product of the 39 
additional thyroidectomy procedures during a decade attributable to rates beyond those 40 
reported for 2002 and the national average hospital cost of an uncomplicated thyroidectomy 41 
in Australia.  42 
 43 
Results: The incidence of both DTC and thyroidectomy doubled in NSW between 2003 and 44 
2012, while the DTC specific mortality rate remained unchanged over the same period. Based 45 
on the 2002 incidence, the projected increase over 10 years (2003-2012) in thyroidectomy 46 
procedures was 2,196. This translates to an extra cost burden of over AUD$ 18,600,000 in 47 
surgery-related healthcare expenditure over one decade in NSW.  48 
 49 
Conclusions: Our findings suggest that, if this rise is solely attributable to overdetection, then 50 
the rising expenditure serves no additional purpose. Reducing unnecessary detection and a 51 
conservative approach to managing DTC are sensible and would lead to millions of dollars in 52 
savings and reduced harms to patients. 53 
54 
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The incidence of thyroid cancer has increased worldwide 3- to 15-fold over the last 56 
two decades, but with no significant increase in mortality (Pellegriti et al., 2013, Ahn et al., 57 
2014). The increase in incidence is largely attributable to increased detection of differentiated 58 
thyroid cancer ([DTC] – i.e. papillary and follicular cancer) (Burgess and Tucker, 2006, 59 
Davies and Welch, 2006, Enewold et al., 2011). Studies have found that the penetrance of 60 
thyroid-cancer screening and fine-needle aspiration (FNA) strongly correlate with the 61 
observed increase in incidence (Burgess and Tucker, 2006, Ahn et al., 2014). Our recent 62 
investigation has also found that the increasing incidence of DTC is not mirrored by the 63 
prevalence of incidental DTC in autopsy studies which has remained stable since 1970 64 
(Furuya-Kanamori et al., 2016). These findings, especially given the latter, establish the case 65 
for the absence of a true population level increase in tumorigenesis and supports the notion 66 
that the increasing burden is driven by increasing detection (Davies and Welch, 2006, Welch 67 
and Black, 2010, Brito et al., 2014, Furuya-Kanamori et al., 2016). 68 
Alongside this increase in DTC incidence, there are reports that suggest that 69 
subsequent surgical intervention (i.e. thyroidectomy) is also increasing (Sung et al., 2014, 70 
Ahn and Welch, 2015). For example, DTC overdetection in small papillary carcinomas is 71 
leading to unnecessary thyroidectomies with no real survival advantage delivered to patients 72 
(Davies and Welch, 2006, Enewold et al., 2011). After surgery most patients would require 73 
lifelong thyroid-replacement therapy, while some patients may have complications from the 74 
surgical procedure such as hypoparathyroidism and paralysis of recurrent or superior 75 
laryngeal nerves (Hartl and Schlumberger, 2013). Therefore, in March 2014 a Physician 76 
Coalition for Prevention of Overdiagnosis of Thyroid Cancer in South Korea wrote an open 77 
letter to the public discouraging routine ultrasonographic screening, this recommendation led 78 
Page 3 of 47
erc@bioscientifica.com






to a 40% decrease in thyroidectomies within the country in the subsequent year (Ahn and 79 
Welch, 2015). 80 
Similar to other countries, DTC incidence has rapidly increased over the last two 81 
decades in Australia (Burgess, 2002, Haggar et al., 2012, Pandeya et al., 2016, Cancer 82 
Australia); however, it is unknown if this has been paralleled by an increase in surgical 83 
intervention rates. We therefore undertook an evaluation of the diagnostic, surgical, and 84 
mortality trend data for DTC from New South Wales (NSW) to estimate the increase in 85 
economic burden of these surgical interventions to the Australian healthcare system and its 86 
impact on DTC specific mortality rates during the last decade.  87 
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Materials and methods 88 
The study was approved by the Australian National University - Science & Medical 89 
Delegated Ethics Review Committee (#2016/030) and conforms to the data-use agreement 90 
from the NSW Health Department. 91 
 92 
Data sources and study population 93 
 Aggregated data from patients diagnosed with thyroid cancer (Cancer Institute NSW, 94 
2016b) and thyroid cancer specific deaths (Cancer Institute NSW, 2016c) in NSW between 95 
January 1982 and December 2012 were retrieved from the Cancer Institute NSW. The NSW 96 
Cancer Registry (NSWCR) is managed by the Cancer Institute NSW. The NSWCR is a 97 
population-based cancer registry that contains records of people with malignant neoplasms in 98 
NSW since 1972. Notification of new cancer cases and cancer deaths is legally required in 99 
NSW and the NSWCR receives data from public and private hospitals, nursing homes, public 100 
and private pathology laboratories, and the Registry of Births, Deaths and Marriage.  101 
Data from patients with thyroid gland malignancies (ICD-10-CM C73) that underwent 102 
partial (ICD-10-AM 30306-00, 30306-01, 30308-00, 30310-00, 90046-00) or total (ICD-10-103 
AM 30296-00, 30296-01, 90046-01, 90046-02) thyroidectomies between January 2002 and 104 
December 2012 in NSW were extracted from the Admitted Patient Data Collection (APDC). 105 
Thyroidectomies with indications other than thyroid cancer (i.e. thyrotoxicosis ICD-10-AM 106 
30309-00) were excluded from the analysis. To avoid the inclusion of recurrent cases of 107 
surgical procedures (e.g. partial thyroidectomy followed by a total thyroidectomy – ICD-10-108 
AM 30297-00, 30297-01, 30297-02) and over estimating the incidence of patients that 109 
underwent a thyroidectomy; if a patient had more than one surgical procedure, only the first 110 
procedure was included for the analysis. The APDC is administered by the NSW Health 111 
Department. The APDC data provides reasonably accurate information on procedures and 112 
Page 5 of 47
erc@bioscientifica.com






comorbidities (Goldsbury et al., 2011, Goldsbury et al., 2012). A detailed description of the 113 
APDC scope, collection methodology, maintenance, and data accuracy is described 114 
elsewhere (Australian Bureau of Statistics, 2008).  115 
116 
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Statistical analyses 117 
Thyroid cancer cases, thyroidectomy procedures, and thyroid cancer specific 118 
mortality in NSW were categorized by year of event (diagnosis or surgical procedure) and 119 
sex. New events were counted within these categories. The population at risk, the population 120 
in NSW, was extracted from the Australian Bureau of Statistics (ABS) and stratified by year 121 
and sex. It should be noted that differentiation of DTC from all thyroid cancers was not 122 
possible and this applies to thyroidectomy as well. Although, the analyses were not DTC-123 
specific, yet the estimated incidence rates reported are deemed to be those for DTC as they 124 
should closely match the DTC-specific incidence due to the small proportion (10% or less) of 125 
other histological types of cancers (i.e. medullary and anaplastic) expected in such cohorts 126 
during the same period (Pandeya et al., 2016). This seems justified since an analysis of a 127 
previous dataset of ours with only DTC confirms that DTC mortality trends  remain 128 
comparable  to those reported here (Mankarios et al., 2014). All subsequent references to 129 
DTC should be understood to refer to DTC without exclusion of the other thyroid cancers.  130 
Poisson regressions models using robust standard errors and the population as the 131 
exposed population at risk were built to model the rates for incident DTC, incident 132 
thyroidectomies, and thyroid cancer specific mortality in NSW by including an interaction 133 
term for continuous year and sex. The predicted number of cases per year and by sex from the 134 
fitted models were used to estimate the incidence of DTC and DTC specific mortality from 135 
1982 to 2012 and thyroidectomy procedures from 2002 to 2012 in NSW per 100,000 136 
population. 137 
The rate observed in 2002 was deemed the baseline from which the increase in the 138 
rate of thyroidectomy was computed over the subsequent decade. The increase in 139 
thyroidectomy rates was therefore estimated for the period 2003-2012 as the difference from 140 
the baseline had it remained at the 2002 levels. To compute the additional number of surgical 141 
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procedures over the last decade, the modelled difference in rates (from 2002 levels) was 142 
multiplied by the population at risk in NSW during each year.  143 
The national average hospital cost of uncomplicated thyroidectomy for 2012-2013 in 144 
Australia was AUD$ 8,500 (Independent Hospital Pricing Authority, 2015). The economic 145 
burden of potentially avoidable thyroidectomy due to the increase in diagnosis to the 146 
Australian healthcare system was estimated as the product of the additional thyroidectomy 147 
within the decade after 2002 and the national average hospital cost of an uncomplicated 148 
thyroidectomy. We did not estimate the costs of complications or ongoing treatment such as 149 
thyroid replacement. All statistical analyses were conducted using Stata® SE, version 14 150 
(Stata Corporation; College Station, TX).  151 
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 Between 1982 and 2012, 13,131 patients were diagnosed with DTC in NSW and 859 153 
had a thyroid cancer specific mortality. The majority of diagnosed patients were females 154 
(n=9,877; 751%). 6,790 thyroidectomies were recorded among patients with DTC between 155 
2002 and 2012 in NSW hospitals. The majority of the thyroidectomy procedures were 156 
performed in women (n=5,485; 8089%) and the median age of the patients was 50 years 157 
(IQR 40-62 years) (Table 1).  158 
The estimated DTC incidence per 100,000 population increased from 34 (females) 159 
and 12 (males) in 1982 to 206 (females) and 68 (males) in 2012. The estimated 160 
thyroidectomy incidence per 100,000 population increased from 91 (females) and 30 161 
(males) in 2002 to 186 (females) and 60 (males) in 2012; while the estimated thyroid cancer 162 
specific mortality rate demonstrated no change over this period or indeed the prior two 163 
decades (Figures 1 and 2 & Supplementary material).  164 
During the decade of interest (2003-2012), there was a two-fold increase in both, 165 
DTC and thyroidectomies among females and males. Since, the percentage of DTC 166 
diagnosed patients getting a thyroidectomy has remained stable, it follows therefore that 167 
watchful waiting is not happening at a greater rate than previously despite DTC incidence 168 
steeply rising (Figures 1 & 2). Based on this increasing incidence, the projected increase in 169 
thyroidectomy was 2,196 (1,667 females; 529 males) cases more than would have happened 170 
if thyroidectomies rates had remained stable subsequent to 2002. This translates to an 171 
increase of AUD$ 18,666,000 ($14,169,500 in females; $4,496,500 in males) in surgery-172 
related healthcare expenditure over one decade in NSW (Figures 1 and 2).   173 
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DTC incidence has increased to epidemic proportions worldwide over the last few 175 
decades. Overdetection has not only increased DTC incidence, but it has also led to a 176 
concurrent increase in thyroidectomy procedures with a huge economic burden on the 177 
healthcare system (Table 2). Over the last decade, we estimate that the number of potentially 178 
avoidable thyroidectomies performed in NSW was 2,196. The increase in thyroidectomy 179 
procedures in NSW over this decade actually approximates the total estimated number of new 180 
cases of thyroid cancer diagnosed Australia-wide in 2016 (2098 new cases) (Cancer 181 
Australia). DTC specific mortality in Australia however has remained essentially unchanged 182 
over the last 30 years (Cancer Australia) and among the thyroid cancer specific deaths 183 
recorded in 2012 in NSW, half of them occurred in patients aged 80 years or above (Cancer 184 
Institute NSW, 2016a). These figures amount to a huge excess in diagnosis and intervention 185 
that do not lead to increased survival for patients (Davies and Welch, 2006, Ito et al., 2010, 186 
Sugitani et al., 2010, Welch and Black, 2010, Ito et al., 2014, Furuya-Kanamori et al., 2016, 187 
Cancer Australia).  188 
It should be emphasised that we base our conclusion regarding the lack of tangible 189 
clinical gain only on the specific mortality rate having remained unchanged. There is, 190 
however, no expectation that intervention may decrease morbidity that does not lead to death. 191 
Unfortunately, these interventions themselves have been associated with morbidities. In fact, 192 
paradoxically there is likely to be an increase in morbidity related to treatment if patients 193 
subject to such (over)diagnosis are given the standard management for thyroid cancer which 194 
includes surgical resection and/or radioiodine therapy (Doi and Woodhouse, 2000, Doi et al., 195 
2007, Haugen et al., 2015). Surgical complications may arise and include 196 
hypoparathyroidism, a life-threatening condition that requires intensive monitoring and 197 
therapy with calcium and vitamin D; laryngeal nerve palsy which will results in voice 198 
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change; and/or require tracheotomy in cases of bilateral nerve damage. Even when the 199 
surgery is complication free, most of the patients will require lifelong surveillance, and 200 
thyroid hormone suppression or replacement which may have longer term metabolic 201 
implications (Hartl and Schlumberger, 2013). 202 
It could be argued that the increased thyroid cancer diagnosis in recent years is 203 
associated with stable mortality because of improvement in diagnosis and management over 204 
time. However, Davies and Welch have pointed out that this is not likely to be true (Davies 205 
and Welch, 2014) because for mortality to remain stable, improvements (in diagnostic 206 
techniques and disease management) have to precisely mirror the increase in thyroid 207 
incidence. Thus, improvements occurring at a faster or slower rate than changes in incidence 208 
rate would certainly alter mortality rates and to assume an exact match between the rising 209 
incidence and the improvements over 30 years is highly implausible. In a previous study, we 210 
demonstrated that the reservoir of incidental DTC has remained stable since 1970 suggesting 211 
that population level of tumorigenesis has remained unchanged (Furuya-Kanamori et al., 212 
2016). Therefore, the most reasonable explanation for the rising thyroid cancer incidence 213 
with stable mortality is that subclinical DTC is increasingly being detected due to the 214 
improvements in diagnostic techniques, but these newly diagnosed subclinical cases may not 215 
progress or will progress so slowly that the patient is more likely to die from other causes.  216 
Overdetection of indolent DTC microcarcinomas could lead to unnecessary economic 217 
burden, while late diagnosis of clinically significant thyroid cancer could worsen clinical 218 
outcome. The current evidence does make the case for the development of strategies to 219 
reduce overdetection (the thyroid should not be examined without a specific indication) as 220 
well as implementation of a more conservative approach to nodule diagnosis through active 221 
surveillance leading on to intervention if thyroid nodules demonstrate progression (i.e. size 222 
and/or characteristics) (Leboulleux et al., 2016). At this point, it is not clear which patients 223 
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are eligible for active surveillance, further studies are required to accurately discriminate 224 
patients who need to undergo thyroid nodule biopsy or active surveillance; as well as to 225 
recognise prognostic factors that would warrant early intervention among the subset of 226 
thyroid cancer patients with more aggressive disease. Currently, nodule size is an important 227 
factor in such decision making, along with family history, exposure to radiation, and age of 228 
the patient (>45 years) (Onitilo et al., 2009, Mankarios et al., 2014, Haugen et al., 2015, 229 
Hoang et al., 2015). Although, differentiation of DTC histopathology (papillary versus 230 
follicular) does not seem to play a major role in decision making, FNA cytology may be 231 
indicated if there are signs of progression or to differentiate DTC from other types of 232 
carcinomas (i.e. medullary and anaplastic) given the different prognosis associated with the 233 
latter.   234 
 In terms of health services expenditure, thyroid gland surgeries in Australia cost on 235 
average AUD$ 8,500; however when there are surgical complications, this amount rapidly 236 
increases to over AUD$ 15,000 (Independent Hospital Pricing Authority, 2015). We used the 237 
average cost of uncomplicated thyroidectomies, which provides a conservative economic 238 
estimate of the burden of increasing diagnosis. Future economic evaluations would need to 239 
take into account additional costs such as diagnosis (e.g. FNA and histopathology 240 
examination), complications during the surgical intervention (e.g. ICU admission), hormone 241 
replacement therapy, and outpatient consultations. Thus, a deferral of surgery can be 242 
expected to lead to significant savings in projected healthcare expenditure of at least AUD$ 4 243 
million per year in the state of NSW. This cost saving over 10 years is weighted heavily 244 
towards the later part of the decade and is a very conservative estimate as it does not take into 245 
account the treatment factors mentioned previously and of course the emotional burden on 246 
patients. Furthermore, given that the DTC incidence rise has been ongoing since the 1980s, 247 
our estimate over only the last decade is probably a considerable underestimate of the 248 
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economic burden as overdetection/thyroidectomy may have increased 4-fold rather than just 249 
2-fold. While, the data suggest a clear economic case for surveillance rather than 250 
intervention, and accumulated evidence from several studies suggest that this would be a safe 251 
approach (Ito et al., 2010, Sugitani et al., 2010, Brito et al., 2014, Ito et al., 2014); the exact 252 
process that should be adopted requires further evidence from prospective clinical studies, 253 
and funding for such studies must be made a priority.   254 
 Our findings should be considered in the light of a few limitations. An important one 255 
was the inability to conduct sub-group analyses by age group, patient ethnicity, tumour size, 256 
and histopathology. However, we were able to stratify the analyses by sex, which is known to 257 
be one of the strongest predictors of DTC incidence and thyroidectomy. We also make the 258 
assumption based on our previous work that the rising trends are representative of 259 
overdiagnosis (Furuya-Kanamori et al., 2016). There have been studies that seem to disagree 260 
and for example, from a SEER database analysis by Enewold et al. (2009) amongst White 261 
women, the rate of increase for papillary thyroid carcinoma >5cm was similar to that for 262 
smaller thyroid cancer. Another study from Spain by Rego-Iraeta et al. (2009) also reported 263 
that the rate of rise in thyroid cancer was observed across all tumour sizes. We agree with the 264 
latter that the incidence of all sizes are rising but a re-analysis of our previous data 265 
(Mankarios et al., 2014) stratified by tumour size and gender clearly demonstrates that the 266 
rate of rise decreases with increasing size, though all sizes are increasingly detected (data not 267 
shown). We believe that this again is consistent with overdiagnosis. Nevertheless, it is 268 
important to distinguish indolent tumours from clinically significant tumours (where delays 269 
in diagnosis are important) and this requires guidance from future studies regarding 270 
delineation of criteria for patients who need to undergo thyroid nodule biopsy for diagnosis of 271 
thyroid cancer (to avoid over-diagnosis of indolent thyroid cancer). Such criteria would likely 272 
be prognostic factors that would assist in identification of more advanced thyroid cancers 273 
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thus avoiding fears that clinicians may delay treatment and increase recurrent/persistent 274 
disease within a selected sub-set of thyroid cancer patients with more aggressive disease.   275 
 In conclusion, the evidence base for avoidable costs to healthcare is clear and savings 276 
expected are substantial from a conservative approach to both thyroid examination (only 277 
when indicated) and management of thyroid cancer when detected. Current evidence suggests 278 
that watchful waiting is a safe route for management of many of the latter patients if due 279 
surveillance is properly managed. What remains to be mapped out is who exactly should be 280 
offered active surveillance and the criteria for subsequent intervention.  281 
Page 14 of 47
erc@bioscientifica.com






Declaration of interest 282 
The authors have no conflicts of interest in the authorship or publication of this article. 283 
 284 
Funding  285 
None 286 
 287 
Authors’ contributions 288 
LFK and SARD contributed to the conception and design of the study. AS and LFK assisted 289 
with data acquisition. LFK conducted the statistical analyses. LFK and SARD drafted the 290 
manuscript. AS, AAO, NB, and PG critically revised the manuscript. LFK, AS, AAO, NB, 291 
PG, and SARD read and approved the final version of the manuscript and agreed to be fully 292 
accountable for ensuring the integrity and accuracy of the work.  293 
Page 15 of 47
erc@bioscientifica.com







AHN, H. S., KIM, H. J. & WELCH, H. G. 2014. Korea's thyroid-cancer "epidemic"- 295 
screening and overdiagnosis. N Engl J Med 371: 1765-7. 296 
AHN, H. S. & WELCH, H. G. 2015. South Korea's thyroid-cancer "Epidemic"- Turning the 297 
tide. N Engl J Med 373: 2389-90. 298 
AUSTRALIAN BUREAU OF STATISTICS. 2008. NSW Health Department, Admitted 299 
Patient Data Collection [Online]. Available: 300 
http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1368.1Explanatory%20Notes1301 
452007 [Accessed September 2017]. 302 
BRITO, J. P., DAVIES, L., ZEBALLOS-PALACIOS, C., MORRIS, J. C. & MONTORI, V. 303 
M. 2014. Papillary lesions of indolent course: reducing the overdiagnosis of indolent 304 
papillary thyroid cancer and unnecessary treatment. Future Oncol 10: 1-4. 305 
BURGESS, J. R. 2002. Temporal trends for thyroid carcinoma in Australia: an increasing 306 
incidence of papillary thyroid carcinoma (1982-1997). Thyroid 12: 141-9. 307 
BURGESS, J. R. & TUCKER, P. 2006. Incidence trends for papillary thyroid carcinoma and 308 
their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. 309 
Thyroid 16: 47-53. 310 
CANCER AUSTRALIA. Thyroid cancer [Online]. Available: 311 
https://canceraustralia.gov.au/affected-cancer/cancer-types/thyroid-cancer/thyroid-312 
cancer-statistics [Accessed September 2017]. 313 
CANCER INSTITUTE NSW. 2016a. Thyroid cancer [Online]. Available: 314 
https://www.cancerinstitute.org.au/understanding-cancer/cancer-in-nsw/thyroid-315 
cancer [Accessed September 2017]. 316 
CANCER INSTITUTE NSW. 2016b. Thyroid cancer - Age Standardised Incidence Rates 317 
[Online]. Available: 318 
http://www.statistics.cancerinstitute.org.au/trends/trends_incid_C73_extall_NSW.htm 319 
[Accessed September 2017]. 320 
CANCER INSTITUTE NSW. 2016c. Thyroid cancer - Age Standardised Mortality Rates 321 
[Online]. Available: 322 
Page 16 of 47
erc@bioscientifica.com







[Accessed September 2017]. 324 
DAVIES, L. & WELCH, H. 2014. Davies and welch draw unfounded conclusions about 325 
thyroid cancer from epidemiological data—reply. JAMA Otolaryngol Head Neck Surg 326 
140: 679. 327 
DAVIES, L. & WELCH, H. G. 2006. Increasing incidence of thyroid cancer in the United 328 
States, 1973-2002. JAMA 295: 2164-7. 329 
DOI, S. A. & WOODHOUSE, N. J. 2000. Ablation of the thyroid remnant and 131I dose in 330 
differentiated thyroid cancer. Clin Endocrinol (Oxf) 52: 765-73. 331 
DOI, S. A. R., WOODHOUSE, N. J., THALIB, L. & ONITILO, A. 2007. Ablation of the 332 
Thyroid Remnant and I-131 Dose in Differentiated Thyroid Cancer: A Meta-Analysis 333 
Revisited. Clin Med Res 5: 87-90. 334 
ENEWOLD, L., ZHU, K., RON, E., MARROGI, A. J., STOJADINOVIC, A., PEOPLES, G. 335 
E. & DEVESA, S. S. 2009. Rising thyroid cancer incidence in the United States by 336 
demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers 337 
Prev 18: 784-91. 338 
ENEWOLD, L. R., ZHOU, J., DEVESA, S. S., BERRINGTON DE GONZALEZ, A., 339 
ANDERSON, W. F., ZAHM, S. H., STOJADINOVIC, A., PEOPLES, G. E., 340 
MARROGI, A. J., POTTER, J. F., MCGLYNN, K. A. & ZHU, K. 2011. Thyroid 341 
cancer incidence among active duty U.S. military personnel, 1990-2004. Cancer 342 
Epidemiol Biomarkers Prev 20: 2369-76. 343 
FURUYA-KANAMORI, L., BELL, K. J., CLARK, J., GLASZIOU, P. & DOI, S. A. 2016. 344 
Prevalence of Differentiated Thyroid Cancer in Autopsy Studies Over Six Decades: A 345 
Meta-Analysis. J Clin Oncol 34: 3672-9. 346 
GOLDSBURY, D. E., ARMSTRONG, K., SIMONELLA, L., ARMSTRONG, B. K. & 347 
O'CONNELL, D. L. 2012. Using administrative health data to describe colorectal and 348 
lung cancer care in New South Wales, Australia: a validation study. BMC Health Serv 349 
Res 12: 1472. 350 
Page 17 of 47
erc@bioscientifica.com






GOLDSBURY, D. E., SMITH, D. P., ARMSTRONG, B. K. & O'CONNELL, D. L. 2011. 351 
Using linked routinely collected health data to describe prostate cancer treatment in 352 
New South Wales, Australia: a validation study. BMC Health Services Res 11: 253. 353 
HAGGAR, F. A., PREEN, D. B., PEREIRA, G., HOLMAN, C. D. & EINARSDOTTIR, K. 354 
2012. Cancer incidence and mortality trends in Australian adolescents and young 355 
adults, 1982-2007. BMC Cancer 12: 151. 356 
HARTL, D. M. & SCHLUMBERGER, M. 2013. Extent of Thyroidectomy and Incidence of 357 
Morbidity: Risk-appropriate Treatment. In: MICCOLI, P., TERRIS, D. J., MINUTO, 358 
M. N. & SEYBT, M. W. (eds.) Thyroid Surgery: Preventing and Managing 359 
Complications. Oxford: Wiley-Blackwell. 360 
HAUGEN, B. R. M., ALEXANDER, E. K., BIBLE, K. C., DOHERTY, G., MANDEL, S. J., 361 
NIKIFOROV, Y. E., PACINI, F., RANDOLPH, G., SAWKA, A., 362 
SCHLUMBERGER, M., SCHUFF, K. G., SHERMAN, S. I., SOSA, J. A., 363 
STEWARD, D., TUTTLE, R. M. M. & WARTOFSKY, L. 2015. 2015 American 364 
Thyroid Association management guidelines for adult patients with thyroid nodules 365 
and differentiated thyroid cancer. Thyroid 26: 1-133. 366 
HOANG, J. K., LANGER, J. E., MIDDLETON, W. D., WU, C. C., HAMMERS, L. W., 367 
CRONAN, J. J., TESSLER, F. N., GRANT, E. G. & BERLAND, L. L. 2015. 368 
Managing incidental thyroid nodules detected on imaging: white paper of the ACR 369 
Incidental Thyroid Findings Committee. J Am Coll Radiol 12: 143-50. 370 
INDEPENDENT HOSPITAL PRICING AUTHORITY. 2015. National Hospital Cost Data 371 
Collection Australian Public Hospitals Cost Report 2012-2013, Round 17 [Online]. 372 
Available: 373 
https://www.ihpa.gov.au/sites/g/files/net636/f/publications/nhcdc_cost_report_2012-374 
2013_round_17_0.pdf [Accessed September 2017]. 375 
ITO, Y., MIYAUCHI, A., INOUE, H., FUKUSHIMA, M., KIHARA, M., HIGASHIYAMA, 376 
T., TOMODA, C., TAKAMURA, Y., KOBAYASHI, K. & MIYA, A. 2010. An 377 
observational trial for papillary thyroid microcarcinoma in Japanese patients. World J 378 
Surg 34: 28-35. 379 
Page 18 of 47
erc@bioscientifica.com






ITO, Y., MIYAUCHI, A., KIHARA, M., HIGASHIYAMA, T., KOBAYASHI, K. & MIYA, 380 
A. 2014. Patient age is significantly related to the progression of papillary 381 
microcarcinoma of the thyroid under observation. Thyroid 24: 27-34. 382 
LEBOULLEUX, S., TUTTLE, R. M., PACINI, F. & SCHLUMBERGER, M. 2016. Papillary 383 
thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet 384 
Diabetes Endocrinol 4: 933-42. 385 
MANKARIOS, D., BAADE, P., YOUL, P., MORTIMER, R. H., ONITILO, A. A., 386 
RUSSELL, A. & DOI, S. A. 2014. Validation of the QTNM staging system for 387 
cancer-specific survival in patients with differentiated thyroid cancer. Endocrine 46: 388 
300-8. 389 
ONITILO, A. A., ENGEL, J. M., LUNDGREN, C. I., HALL, P., THALIB, L. & DOI, S. A. 390 
2009. Simplifying the TNM system for clinical use in differentiated thyroid cancer. J 391 
Clin Oncol 27: 1872-8. 392 
PANDEYA, N., MCLEOD, D. S., BALASUBRAMANIAM, K., BAADE, P. D., YOUL, P. 393 
H., BAIN, C. J., ALLISON, R. & JORDAN, S. J. 2016. Increasing thyroid cancer 394 
incidence in Queensland, Australia 1982-2008 - true increase or overdiagnosis? Clin 395 
Endocrinol 84: 257-64. 396 
PELLEGRITI, G., FRASCA, F., REGALBUTO, C., SQUATRITO, S. & VIGNERI, R. 2013. 397 
Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk 398 
factors. J Cancer Epidemiol 2013: 965212. 399 
REGO-IRAETA, A., PEREZ-MENDEZ, L. F., MANTINAN, B. & GARCIA-MAYOR, R. 400 
V. 2009. Time trends for thyroid cancer in northwestern Spain: true rise in the 401 
incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid 19: 333-402 
40. 403 
SUGITANI, I., TODA, K., YAMADA, K., YAMAMOTO, N., IKENAGA, M. & 404 
FUJIMOTO, Y. 2010. Three distinctly different kinds of papillary thyroid 405 
microcarcinoma should be recognized: our treatment strategies and outcomes. World 406 
J Surg 34: 1222-31. 407 
Page 19 of 47
erc@bioscientifica.com






SUNG, M. W., PARK, B., AN, S. Y., HAH, J. H., JUNG, Y. H. & CHOI, H. G. 2014. 408 
Increasing thyroid cancer rate and the extent of thyroid surgery in Korea. PLoS One 9: 409 
e113464. 410 
WELCH, H. G. & BLACK, W. C. 2010. Overdiagnosis in cancer. J Natl Cancer Inst 102: 411 
605-13. 412 
Table Title 413 
 414 
Table 1. Patient’s characteristics 415 
 416 




Figure Legend 421 
 422 
Figure 1. Observed (circles) and modelled (dashed lines) incidence per 100,000 for DTC 423 
(blue), thyroidectomies (red), and DTC specific mortality (green) over time in females. Gray 424 
shaded area represents the excess (potentially avoidable) thyroidectomies performed due to 425 
the increase in diagnosis over the last decade and the excess in surgery-related healthcare 426 
expenditure associated with this. 427 
 428 
Figure 2. Observed (circles) and modelled (dashed lines) incidence per 100,000 for DTC 429 
(blue), thyroidectomies (red), and DTC specific mortality (green) over time in males. Gray 430 
shaded area represents the excess (potentially avoidable) thyroidectomies performed due to 431 
the increase in diagnosis over the last decade and the excess in surgery-related healthcare 432 
expenditure associated with this. 433 
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Table 1. Patient’s characteristics 
 









Female sex 9,877 (75·2%) 5,147 (75·8%) 513 (59·7%) 
Age in years, median (IQR) - 50 (40-62) - 
Type of thyroidectomy    
 Partial - 1,305 (19·2%) - 
 Total - 5,485 (80·8%) - 
Year    
 1982-85 552 - 90 
 1986-89 693 - 96 
 1990-93 977 - 92 
 1994-97 1290 - 103 
 1998-01 1675 - 107 
 2002-05 2217 1823 132 
 2006-09 2872 2453 134 
 2010-2012 2845 2514 105 
IQR inter-quartile range 
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Table 2. Worldwide trends in thyroid cancer incidence, thyroidectomy rate and mortality 
rate 
 
Country Thyroid cancer incidence Thyroidectomy rate Mortality rate 
Canada Increased 5-fold 
(1970-2012) 
Increased 13%  
(2003-2011) 
Remained stable  
(1970-2012) 






Switzerland Increased 2- and 1.5- fold 
in females and males, 
respectively 
(1998-2012) 
Increased 4- and 3-fold 
in females and males, 
respectively 
(1998-2012) 
Decreased by 30% 
(1998-2012) 






UK Increased 2.2-fold 
(1993-2014) 
Not available Remained stable 
(1993-2014) 
* Number of thyroidectomies, not rates 
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Figure 1. Observed (circles) and modelled (dashed lines) incidence per 100,000 for DTC (blue), 
thyroidectomies (red), and DTC specific mortality (green) over time in females. Gray shaded area represents 
the excess (potentially avoidable) thyroidectomies performed due to the increase in diagnosis over the last 
decade and the excess in surgery-related healthcare expenditure associated with this.  
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Figure 2. Observed (circles) and modelled (dashed lines) incidence per 100,000 for DTC (blue), 
thyroidectomies (red), and DTC specific mortality (green) over time in males. Gray shaded area represents 
the excess (potentially avoidable) thyroidectomies performed due to the increase in diagnosis over the last 
decade and the excess in surgery-related healthcare expenditure associated with this.  
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Table S1. Estimated incidence and its 95% confidence interval of thyroid cancer, thyroidectomy, and thyroid cancer specific mortality 
per 100,000 population by sex. 
Year Female Males 
Thyroid cancer Thyroidectomy Thyroid cancer 
mortality 
Thyroid cancer Thyroidectomy Thyroid cancer 
mortality 
1982 3·5 (3·2-3·7) - 0·5 (0·4-0·6) 1·2 (1·1-1·2) - 0·3 (0·3-0·4) 
1983 3·7 (3·5-3·9) - 0·5 (0·4-0·6) 1·2 (1·2-1·3) - 0·3 (0·3-0·4) 
1984 3·9 (3·7-4·1) - 0·5 (0·4-0·6) 1·3 (1·2-1·4) - 0·3 (0·3-0·4) 




0·5 (0·4-0·6) 1·5 (1·4-1·6) 
- 
0·3 (0·3-0·4) 
1987 4·7 (4·4-4·9) - 0·5 (0·4-0·6) 1·6 (1·5-1·6) - 0·3 (0·3-0·4) 
1988 4·9 (4·7-5·2) - 0·5 (0·4-0·6) 1·6 (1·6-1·7) - 0·3 (0·3-0·4) 
1989 5·2 (5·0-5·5) - 0·5 (0·4-0·6) 1·8 (1·7-1·8) - 0·3 (0·3-0·4) 




0·5 (0·5-0·6) 2·0 (1·9-2·1) 
- 
0·3 (0·3-0·4) 
1992 6·3 (6·0-6·5) - 0·5 (0·5-0·6) 2·1 (2·0-2·2) - 0·3 (0·3-0·4) 
1993 6·6 (6·4-6·9) - 0·5 (0·5-0·6) 2·2 (2·1-2·3) - 0·3 (0·3-0·4) 




0·5 (0·5-0·6) 2·5 (2·4-2·6) 
- 
0·4 (0·3-0·4) 
1996 7·9 (7·7-8·2) - 0·5 (0·5-0·6) 2·7 (2·5-2·8) - 0·4 (0·3-0·4) 
1997 8·4 (8·2-8·7) - 0·5 (0·5-0·6) 2·8 (2·7-2·9) - 0·4 (0·3-0·4) 
1998 8·9 (8·7-9·2) - 0·5 (0·5-0·6) 3·0 (2·9-3·1) - 0·4 (0·3-0·4) 
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0·5 (0·5-0·6) 3·4 (3·2-3·5) 
- 
0·4 (0·3-0·4) 
2001 10·7 (10·4-10·9) - 0·5 (0·5-0·6) 3·6 (3·4-3·7) - 0·4 (0·3-0·4) 
2002 11·3 (11·1-11·6) 9·1 (8·6-9·7) 0·5 (0·5-0·6) 3·8 (3·7-3·9) 3·0 (2·7-3·2) 0·4 (0·3-0·4) 
2003 12·0 (11·8-12·3) 9·8 (9·3-10·3) 0·5 (0·5-0·6) 4·0 (3·9-4·2) 3·2 (2·9-3·4) 0·4 (0·3-0·4) 
2004 12·8 (12·5-13·1) 10·5 (10·0-11·0) 0·5 (0·5-0·6) 4·3 (4·1-4·4) 3·4 (3·2-3·7) 0·4 (0·3-0·4) 
2005 
13·6 (13·3-13·9) 11·3 (10·8-11·8) 0·6 (0·5-0·6) 4·5 (4·4-4·7) 3·7 (3·4-3·9) 0·4 (0·3-0·4) 
2006 14·4 (14·1-14·7) 12·1 (11·7-12·6) 0·6 (0·5-0·6) 4·8 (4·6-5·0) 3·9 (3·7-4·2) 0·4 (0·3-0·4) 
2007 15·3 (14·9-15·6) 13·0 (12·6-13·5) 0·6 (0·5-0·6) 5·1 (4·9-5·3) 4·2 (4·0-4·5) 0·4 (0·3-0·4) 
2008 16·2 (15·8-16·6) 14·0 (13·6-14·4) 0·6 (0·5-0·6) 5·4 (5·2-5·6) 4·5 (4·3-4·8) 0·4 (0·3-0·4) 
2009 17·2 (16·7-17·7) 15·0 (14·6-15·5) 0·6 (0·5-0·6) 5·7 (5·5-6·0) 4·9 (4·6-5·2) 0·4 (0·3-0·4) 
2010 
18·2 (17·7-18·8) 16·2 (15·6-16·7) 0·6 (0·5-0·6) 6·1 (5·8-6·4) 5·2 (4·9-5·6) 0·4 (0·3-0·4) 
2011 19·4 (18·8-19·9) 17·4 (16·7-18·0) 0·6 (0·5-0·7) 6·5 (6·2-6·8) 5·6 (5·3-6·0) 0·4 (0·3-0·4) 
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Background: The incidence of differentiated thyroid cancer (DTC) has rapidly increased 32 
worldwide over the last decades. It is unknown if the increase in diagnosis has been mirrored 33 
by an increase in thyroidectomy rates with the concomitant economic impact that this would 34 
have on the healthcare system. 35 
 36 
Methods: DTC and thyroidectomy incidence as well as DTC specific mortality were 37 
modelled using Poisson regression in New South Wales (NSW), Australia per year and by 38 
sex. The incidence of 2002 was the point from which the increase in rates were assessed 39 
cumulatively over the subsequent decade. The economic burden of potentially avoidable 40 
thyroidectomies due to the increase in diagnosis was estimated as the product of the 41 
additional thyroidectomy procedures during a decade attributable to rates beyond those 42 
reported for 2002 and the national average hospital cost of an uncomplicated thyroidectomy 43 
in Australia.  44 
 45 
Results: The incidence of both DTC and thyroidectomy doubled in NSW between 2003 and 46 
2012, while the DTC specific mortality rate remained unchanged over the same period. Based 47 
on the 2002 incidence, the projected increase over 10 years (2003-2012) in thyroidectomy 48 
procedures was 2,196. This translates to an extra cost burden of over AUD$ 18,600,000 in 49 
surgery-related healthcare expenditure over one decade in NSW.  50 
 51 
Conclusions: Our findings suggest that, if this rise is solely attributable to overdetection, then 52 
the rising expenditure serves no additional purpose. Reducing unnecessary detection and a 53 
conservative approach to managing DTC are sensible and would lead to millions of dollars in 54 
savings and reduced harms to patients. 55 
56 
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The incidence of thyroid cancer has increased worldwide 3- to 15-fold over the last 58 
two decades, but with no significant increase in mortality (Pellegriti et al., 2013, Ahn et al., 59 
2014). The increase in incidence is largely attributable to increased detection of differentiated 60 
thyroid cancer ([DTC] – i.e. papillary and follicular cancer) (Burgess and Tucker, 2006, 61 
Davies and Welch, 2006, Enewold et al., 2011). Studies have found that the penetrance of 62 
thyroid-cancer screening and fine-needle aspiration (FNA) strongly correlate with the 63 
observed increase in incidence (Burgess and Tucker, 2006, Ahn et al., 2014). Our recent 64 
investigation has also found that the increasing incidence of DTC is not mirrored by the 65 
prevalence of incidental DTC in autopsy studies which has remained stable since 1970 66 
(Furuya-Kanamori et al., 2016). These findings, especially given the latter, establish the case 67 
for the absence of a true population level increase in tumorigenesis and supports the notion 68 
that the increasing burden is driven by increasing detection (Davies and Welch, 2006, Welch 69 
and Black, 2010, Brito et al., 2014, Furuya-Kanamori et al., 2016). 70 
Alongside this increase in DTC incidence, there are reports that suggest that 71 
subsequent surgical intervention (i.e. thyroidectomy) is also increasing (Sung et al., 2014, 72 
Ahn and Welch, 2015). For example, DTC overdetection, in small papillary carcinomas, is 73 
leading to unnecessary thyroidectomies with no real survival advantage delivered to patients 74 
(Davies and Welch, 2006, Enewold et al., 2011). After surgery most patients would require 75 
lifelong thyroid-replacement therapy, while some patients may have complications from the 76 
surgical procedure such as hypoparathyroidism and paralysis of recurrent or superior 77 
laryngeal nerves (Hartl and Schlumberger, 2013). Therefore, in March 2014 a Physician 78 
Coalition for Prevention of Overdiagnosis of Thyroid Cancer in South Korea wrote an open 79 
letter to the public discouraging routine ultrasonographicy screening, this recommendation 80 
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led to a 40% decrease in thyroidectomies within the country in the subsequent year (Ahn and 81 
Welch, 2015). 82 
Similar to other countries, DTC incidence has rapidly increased over the last two 83 
decades in Australia (Burgess, 2002, Haggar et al., 2012, Pandeya et al., 2016, Cancer 84 
Australia); however, it is unknown if this has been paralleled by an increase in surgical 85 
intervention rates. We therefore undertook an evaluation of the diagnostic, surgical, and 86 
mortality trend data for DTC from New South Wales (NSW) to estimate the increase in 87 
economic burden of these surgical interventions to the Australian healthcare system and its 88 
impact on DTC specific mortality rates during the last decade.  89 
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Materials and methods 90 
The study was approved by the Australian National University - Science & Medical 91 
Delegated Ethics Review Committee (#2016/030) and conforms to the data-use agreement 92 
from the NSW Health Department. 93 
 94 
Data sources and study population 95 
 Aggregated data from patients diagnosed with thyroid cancer (Cancer Institute NSW, 96 
2016b) and thyroid cancer specific deaths (Cancer Institute NSW, 2016c) in NSW between 97 
January 1982 and December 2012 were retrieved from the Cancer Institute NSW. The NSW 98 
Cancer Registry (NSWCR) is managed by the Cancer Institute NSW. The NSWCR is a 99 
population-based cancer registry that contains records of people with malignant neoplasms in 100 
NSW since 1972. Notification of new cancer cases and cancer deaths is legally required in 101 
NSW and the NSWCR receives data from public and private hospitals, nursing homes, public 102 
and private pathology laboratories, and the Registry of Births, Deaths and Marriage.  103 
Data from patients with thyroid gland malignancies (ICD-10-CM C73) that underwent 104 
partial (ICD-10-AM 30306-00, 30306-01, 30308-00, 30310-00, 90046-00) or total (ICD-10-105 
AM 30296-00, 30296-01, 90046-01, 90046-02) thyroidectomies between January 2002 and 106 
December 2012 in NSW were extracted from the Admitted Patient Data Collection (APDC). 107 
Thyroidectomies with indications other than thyroid cancer (i.e. thyrotoxicosis ICD-10-AM 108 
30309-00) were excluded from the analysis. To avoid the inclusion of recurrent cases of 109 
surgical procedures (e.g. partial thyroidectomy followed by a total thyroidectomy – ICD-10-110 
AM 30297-00, 30297-01, 30297-02) and over estimating the incidence of patients that 111 
underwent a thyroidectomy; if a patient had more than one surgical procedure, only the first 112 
procedure was included for the analysis. The APDC is administered by the NSW Health 113 
Department. The APDC data provides reasonably accurate information on procedures and 114 
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comorbidities (Goldsbury et al., 2011, Goldsbury et al., 2012). A detailed description of the 115 
APDC scope, collection methodology, maintenance, and data accuracy is described 116 
elsewhere (Australian Bureau of Statistics, 2008).  117 
118 
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Statistical analyses 119 
Thyroid cancer cases, thyroidectomy procedures, and thyroid cancer specific 120 
mortality in NSW were categorized by year of event (diagnosis or surgical procedure) and 121 
sex. New events were counted within these categories. The population at risk, the population 122 
in NSW, was extracted from the Australian Bureau of Statistics (ABS) and stratified by year 123 
and sex. It should be noted that differentiation of DTC from all thyroid cancers was not 124 
possible and this applies to thyroidectomy as well. Although, the analyses were not DTC-125 
specific, yet the estimated incidence rates reported are deemed to be those for DTC as they 126 
should closely match the DTC-specific incidence due to the small proportion (10% or less) of 127 
other histological types of cancers (i.e. medullary and anaplastic) expected in such cohorts 128 
during the same period (Pandeya et al., 2016). This seems justified since In addition, we an 129 
analysised of a previous dataset of ours with only DTC and confirmsed that DTC mortality 130 
trends indeed remained remain comparable identical with to thoseat reported here (Mankarios 131 
et al., 2014). All subsequent references to DTC should be understood to refer to DTC without 132 
exclusion of the other thyroid cancers.  133 
Poisson regressions models using robust standard errors and the population as the 134 
exposed population at risk were built to model the rates for incident DTC, incident 135 
thyroidectomies, and thyroid cancer specific mortality in NSW by including an interaction 136 
term for continuous year and sex. The predicted number of cases per year and by sex from the 137 
fitted models were used to estimate the incidence of DTC and DTC specific mortality from 138 
1982 to 2012 and thyroidectomy procedures from 2002 to 2012 in NSW per 100,000 139 
population. 140 
The rate observed in 2002 was deemed the baseline from which the increase in the 141 
rate of thyroidectomy was computed over the subsequent decade. The increase in 142 
thyroidectomy rates was therefore estimated for the period 2003-2012 as the difference from 143 
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the baseline had it remained at the 2002 levels. To compute the additional number of surgical 144 
procedures over the last decade, the modelled difference in rates (from 2002 levels) was 145 
multiplied by the population at risk in NSW during each year.  146 
The national average hospital cost of uncomplicated thyroidectomy for 2012-2013 in 147 
Australia was AUD$ 8,500 (Independent Hospital Pricing Authority, 2015). The economic 148 
burden of potentially avoidable thyroidectomy due to the increase in diagnosis to the 149 
Australian healthcare system was estimated as the product of the additional thyroidectomy 150 
within the decade after 2002 and the national average hospital cost of an uncomplicated 151 
thyroidectomy. We did not estimate the costs of complications or ongoing treatment such as 152 
thyroid replacement. All statistical analyses were conducted using Stata® SE, version 14 153 
(Stata Corporation; College Station, TX).  154 
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 Between 1982 and 2012, 13,131 patients were diagnosed with DTC in NSW and 859 156 
had a thyroid cancer specific mortality. The majority of diagnosed patients were females 157 
(n=9,877; 751%). 6,790 thyroidectomies were recorded among patients with DTC between 158 
2002 and 2012 in NSW hospitals. The majority of the thyroidectomy procedures were 159 
performed in women (n=5,485; 8089%) and the median age of the patients was 50 years 160 
(IQR 40-62 years) (Table 1).  161 
The estimated DTC incidence per 100,000 population increased from 34 (females) 162 
and 12 (males) in 1982 to 206 (females) and 68 (males) in 2012. The estimated 163 
thyroidectomy incidence per 100,000 population increased from 91 (females) and 30 164 
(males) in 2002 to 186 (females) and 60 (males) in 2012; while the estimated thyroid cancer 165 
specific mortality rate demonstrated no change over this period or indeed the prior two 166 
decades (Figures 1 and 2 & Supplementary material).  167 
During the decade of interest (2003-2012), there was a two-fold increase in both, 168 
DTC and thyroidectomies among females and males. Since, the percentage of DTC 169 
diagnosed patients getting a thyroidectomy has remained stable, therefore it follows therefore 170 
that watchful waiting is not happening at a greater rate than previously despite DTC 171 
incidence steeply rising (Figures 1 & 2). Based on this increasing incidence, the projected 172 
increase in thyroidectomy was 2,196 (1,667 females; 529 males) cases more than would have 173 
happened if thyroidectomies rates had remained stable subsequent to 2002. This translates to 174 
an increase of AUD$ 18,666,000 ($14,169,500 in females; $4,496,500 in males) in surgery-175 
related healthcare expenditure over one decade in NSW (Figures 1 and 2).   176 
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DTC incidence has increased to epidemic proportions worldwide over the last few 178 
decades. Overdetection has not only increased DTC incidence, but it has also led to a 179 
concurrent increase in thyroidectomy procedures with a huge economic burden on the 180 
healthcare system (Table 2). Over the last decade, we estimate that the number of potentially 181 
avoidable thyroidectomies performed in NSW was 2,196. The increase in thyroidectomy 182 
procedures in NSW over this decade actually approximates the total estimated number of new 183 
cases of thyroid cancer diagnosed Australia-wide in 2016 (2098 new cases) (Cancer 184 
Australia). DTC specific mortality in Australia however has remained essentially unchanged 185 
over the last 30 years (Cancer Australia) and among the thyroid cancer specific deaths 186 
recorded in 2012 in NSW, half of them occurred in patients aged 80 years or above (Cancer 187 
Institute NSW, 2016a). These figures amount to a huge excess in diagnosis and intervention 188 
that do not lead to increased survival for patients (Davies and Welch, 2006, Ito et al., 2010, 189 
Sugitani et al., 2010, Welch and Black, 2010, Ito et al., 2014, Furuya-Kanamori et al., 2016, 190 
Cancer Australia).  191 
It should be emphasised that we base our conclusion regarding the lack of tangible 192 
clinical gain only on the specific mortality rate having remained unchanged., There is, 193 
however, no expectation that intervention may decrease morbidity that does not lead to death. 194 
Unfortunately, these interventions themselves have been associated with morbidities. In fact, 195 
paradoxically there is likely to be an increase in morbidity related to treatment if patients 196 
subject to such (over)diagnosis are given the standard management for thyroid cancer which 197 
includes surgical resection and/or radioiodine therapy (Doi and Woodhouse, 2000, Doi et al., 198 
2007, Haugen et al., 2015). Surgical complications may arise and include 199 
hypoparathyroidism, a life-threatening condition that requires intensive monitoring and 200 
therapy with calcium and vitamin D; laryngeal nerve palsy which will results in voice 201 
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change; and/or require tracheotomy in cases of bilateral nerve damage. Even when the 202 
surgery is complication free, most of the patients will require lifelong surveillance, and 203 
thyroid hormone suppression or replacement which may have longer term metabolic 204 
implications (Hartl and Schlumberger, 2013). 205 
It could be argued that the increased thyroid cancer diagnosis in recent years is 206 
associated with stable mortality because of improvement in diagnosis and management over 207 
time. However, Davies and Welch have pointed out that this is not likely to be true (Davies 208 
and Welch, 2014) because for mortality to remain stable, improvements (in diagnostic 209 
techniques and disease management) have to precisely mirror the increase in thyroid 210 
incidence. Thus, improvements occurring at a faster or slower rate than changes in incidence 211 
rate would certainly alter mortality rates and to assume an exact match between the rising 212 
incidence and the improvements over 30 years is highly implausible. In a previous study, we 213 
demonstrated that the reservoir of incidental DTC has remained stable since 1970 suggesting 214 
that population level of tumorigenesis has remained unchanged (Furuya-Kanamori et al., 215 
2016). Therefore, the most reasonable explanation for the rising thyroid cancer incidence 216 
with stable mortality is that subclinical DTC is increasingly being detected due to the 217 
improvements in diagnostic techniques, but these newly diagnosed subclinical cases may not 218 
progress or will progress so slowly that the patient is more likely to die from other causes.  219 
Overdetection of indolent DTC microcarcinomas could lead to unnecessary economic 220 
burden, while late diagnosis of clinically significant thyroid cancer could worsen clinical 221 
outcome. The current evidence does make the case for the development of strategies to 222 
reduce overdetection (the thyroid should not be examined without a specific indication) as 223 
well as implementation of a more conservative approach to nodule diagnosis through active 224 
surveillance leading on to intervention if thyroid nodules demonstrate progression (i.e. size 225 
and/or characteristics) (Leboulleux et al., 2016). At this point, it is not clear which patients 226 
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are eligible for active surveillance, further studies are required to accurately discriminate 227 
patients who need to undergo thyroid nodule biopsy or active surveillance; as well as to 228 
recognise prognostic factors that would warrant early intervention among the subset of 229 
thyroid cancer patients with more aggressive disease. Currently, nodule size is an important 230 
factor in such decision making, along with family history, exposure to radiation, and age of 231 
the patient (>45 years) (Onitilo et al., 2009, Mankarios et al., 2014, Haugen et al., 2015, 232 
Hoang et al., 2015). Although, differentiation of DTC histopathology (papillary versus 233 
follicular) does not seem to play a major role in decision making, FNA cytology may be 234 
indicated if there are signs of progression or to differentiate DTC from other types of 235 
carcinomas (i.e. medullary and anaplastic) given the different prognosis associated with the 236 
latter.   237 
 In terms of health services expenditure, thyroid gland surgeries in Australia cost on 238 
average AUD$ 8,500; however when there are surgical complications, this amount rapidly 239 
increases to over AUD$ 15,000 (Independent Hospital Pricing Authority, 2015). We used the 240 
average cost of uncomplicated thyroidectomies, which provides a conservative economic 241 
estimate of the burden of increasing diagnosis. Future economic evaluations would need to 242 
take into account additional costs such as diagnosis (e.g. FNA and histopathology 243 
examination), complications during the surgical intervention (e.g. ICU admission), hormone 244 
replacement therapy, and outpatient consultations. Thus, a deferral of surgery can be 245 
expected to lead to significant savings in projected healthcare expenditure of at least AUD$ 4 246 
million per year in the state of NSW. This cost saving over 10 years is weighted heavily 247 
towards the later part of the decade and is a very conservative estimate as it does not take into 248 
account the treatment factors mentioned previously and of course the emotional burden on 249 
patients. Furthermore, given that the DTC incidence rise has been ongoing since the 1980s, 250 
our estimate over only the last decade is probably a considerable underestimate of the 251 
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economic burden as overdetection/thyroidectomy may have increased 4-fold rather than just 252 
2-fold. While, the data suggest a clear economic case for surveillance rather than 253 
intervention, and accumulated evidence from several studies suggest that this would be a safe 254 
approach (Ito et al., 2010, Sugitani et al., 2010, Brito et al., 2014, Ito et al., 2014); the exact 255 
process that should be adopted requires further evidence from prospective clinical studies, 256 
and funding for such studies must be made a priority.   257 
 Our findings should be considered in the light of a few limitations. An important one 258 
was the inability to conduct sub-group analyses by age group, patient ethnicity, tumour size, 259 
and histopathology. However, we were able to stratify the analyses by sex, which is known to 260 
be one of the strongest predictors of DTC incidence and thyroidectomy. We also make the 261 
assumption based on our previous work that the rising trends are representative of 262 
overdiagnosis (Furuya-Kanamori et al., 2016). There have been studies that seem to disagree 263 
and for example, from a SEER database analysis by Enewold et al. (2009) amongst White 264 
women, the rate of increase for papillary thyroid carcinoma >5cm was similar to that for 265 
smaller thyroid cancer. Another study from Spain by Rego-Iraeta et al. (2009) also reported 266 
that the rate of rise in thyroid cancer was observed across all tumour sizes. We agree with the 267 
latter that the incidence of all sizes are rising but a re-analysis of our previous data 268 
(Mankarios et al., 2014) stratified by tumour size and gender clearly demonstrates that the 269 
rate of rise decreases with increasing size, though all sizes are increasingly detected (data not 270 
shown). We believe that this again is consistent with overdiagnosis. Nevertheless, it is 271 
important to distinguish indolent tumours from clinically significant tumours (where delays 272 
in diagnosis are important) and this requires guidance from future studies regarding 273 
delineation of criteria for patients who need to undergo thyroid nodule biopsy for diagnosis of 274 
thyroid cancer (to avoid over-diagnosis of indolent thyroid cancer). Such criteria would likely 275 
be prognostic factors that would assist in identification of more advanced thyroid cancers 276 
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thus avoiding fears that clinicians may delay treatment and increase recurrent/persistent 277 
disease within a selected sub-set of thyroid cancer patients with more aggressive disease.   278 
 In conclusion, the evidence base for avoidable costs to healthcare is clear and savings 279 
expected are substantial from a conservative approach to both thyroid examination (only 280 
when indicated) and management of thyroid cancer when detected. Current evidence suggests 281 
that watchful waiting is a safe route for management of many of the latter patients if due 282 
surveillance is properly managed. What remains to be mapped out is who exactly should be 283 
offered active surveillance and the criteria for subsequent intervention.  284 
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Table Title 417 
 418 
Table 1. Patient’s characteristics 419 
 420 




Figure Legend 425 
 426 
Figure 1. Observed (circles) and modelled (dashed lines) incidence per 100,000 for DTC 427 
(blue), thyroidectomies (red), and DTC specific mortality (green) over time in females. Gray 428 
shaded area represents the excess (potentially avoidable) thyroidectomies performed due to 429 
the increase in diagnosis over the last decade and the excess in surgery-related healthcare 430 
expenditure associated with this. 431 
 432 
Figure 2. Observed (circles) and modelled (dashed lines) incidence per 100,000 for DTC 433 
(blue), thyroidectomies (red), and DTC specific mortality (green) over time in males. Gray 434 
shaded area represents the excess (potentially avoidable) thyroidectomies performed due to 435 
the increase in diagnosis over the last decade and the excess in surgery-related healthcare 436 
expenditure associated with this. 437 
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